Basilea Pharmaceutica
BSLN.SW
#6400
Rank
$0.58 B
Marketcap
$48.18
Share price
-0.71%
Change (1 day)
24.85%
Change (1 year)

P/E ratio for Basilea Pharmaceutica (BSLN.SW)

P/E ratio at the end of 2023: 39.5

According to Basilea Pharmaceutica's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 46.5341. At the end of 2023 the company had a P/E ratio of 39.5.

P/E ratio history for Basilea Pharmaceutica from 2004 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202339.5-17.76%
202248.0-164.35%
2021-74.696.74%
2020-37.950.15%
2019-25.360.45%
2018-15.7-67.06%
2017-47.8181.11%
2016-17.0-5.99%
2015-18.1-28.48%
2014-25.3-20.57%
2013-31.8273.67%
2012-8.5232.08%
2011-6.45-202.93%
20106.27-202.42%
2009-6.12-48.87%
2008-12.0-42.14%
2007-20.7-23.4%
2006-27.0-14.43%
2005-31.5188.64%
2004-10.9

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.